Liso-cel therapy significantly improves response rates and survival outcomes in relapsed/refractory CLL/SLL patients compared to standard-of-care treatments. The TRANSCEND CLL 004 trial showed a 52.5% ...
Lisocabtagene maraleucel (liso-cel) shows high response rates in heavily pretreated patients with relapsed or refractory chronic lymphocytic leukemia (CLL), with a CR/CRu rate of 60% and ORR of 83.3%.
Cancer Surveillance in the United States in Jeopardy: Leveraging 21st Century Technology to Enhance Public Health We report 3-year follow-up results from TRANSFORM comparing lisocabtagene maraleucel ...
The approval fills a void for patients with CLL or SLL whose disease progresses after treatment with a BTK inhibitor and a BCL-2 inhibitor; until now, there has been no standard of care. FDA granted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results